CD47 and neoplasm: Currently, several solutions have already been developed to tackle the on‐target toxicities thus advancing CD47 antibodies to the clinics, e.g., controlling the therapeutic dose, differentiating erythrocyte CD47 from tumor cell CD47 according to their distinct modifications and conformations, etc.,[5, 33] whereas much efforts are needed when adapting case‐by‐case solutions to other antibodies and antibody‐based systems.